Meeting
2013 ASCO Annual Meeting
Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.
Authors
Neil Lorne Berinstein
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Neil Lorne Berinstein , Amit M. Oza , Kunle Odunsi , Mohan Karkada , Jeannine A Villella , John J. Nemunaitis , Michael Morse , Tanja Pejovic , James Bentley , Rita Nigam , Genevieve Weir , Lisa MacDonald , Marianne Stanford , Tomasz Burzykowski , Marc Mansour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
NCT01416038
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3030)
DOI
10.1200/jco.2013.31.15_suppl.3030
Abstract #
3030
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I trial of a novel DNA vaccine in patients (pts) with smoldering Waldenstrom macroglobulinemia (sWM).
First Author: Sheeba K. Thomas
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I safety study of oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.
First Author: Boris Minev
Poster
2017 ASCO Annual Meeting
A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.
First Author: Chrisann Kyi
Poster
2016 ASCO Annual Meeting
Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity.
First Author: John Ben Liao